Mice that received combination therapy (DHA 10 mg/kg/day and Apo2L/TRAIL 50 μg/day) experienced a significantly larger reduction in tumour volume compared to those that received DHA or Apo2L/TRAIL monotherapy. The gene discussed is TNFSF10; the disease is neoplasm.